Alphabet Inc. Arcus Biosciences, Inc. Transaction History

Alphabet Inc.

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Nov 14, 2022	SELL	$17.23 - $37.73 $44.2 Million - $96.7 Million	-2,563,441 Closed	0 $0
Q4 2021 Nov 14, 2022	SELL	$31.38 - $48.47 $48.2 Million - $74.5 Million	-1,537,034 Reduced 37.48%	2,563,441 $104 Million
Q3 2021 Nov 14, 2022	SELL	$26.93 - $37.68 $13.8 Million - $19.3 Million	-513,343 Reduced 11.13%	4,100,475 $143 Million
Q2 2021 Nov 14, 2022	SELL	$22.75 - $35.77 $2.49 Million - $3.92 Million	-109,530 Reduced 2.32%	4,613,818 $127 Million
Q1 2021 Nov 14, 2022	SELL	$26.16 - $41.39 $8.54 Million - $13.5 Million	-326,438 Reduced 6.46%	4,723,348 $133 Million
Q1 2018 Nov 14, 2022	BUY	$15.44 - $17.71 $78 Million - $89.4 Million	5,049,786 New	5,049,786 $78 Million

201

51.7M

236K

141K

Ticker RCUS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 72,160,000
Market Cap $1.14B
Description
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...

Get notified when there are updates to the investment portfolio of Alphabet Inc., based on Form 13F filings with the SEC.

Stay updated on Alphabet Inc. with notifications on news.